Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

294
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
294
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

585
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
585
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the determinants of FVIII/FIX levels, bleeding score, and health-related quality of life in the Canadian hemophilia carriers (CHiC) study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Selective Serotonin Reuptake Inhibitors for Children with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.

Clinical medicine insights. Pediatrics·2026
Same author

Hb F-SickKids (<i>HBG2</i>: C.308A > G): A Novel γ-Globin Variant Associated with Transient Neonatal Cyanosis.

Hemoglobin·2026
Same author

Understanding Transformer-Based Classifications of Medical Text Using a Large Language Model for the Attribution of Feature Importance: Proof-of-Concept Algorithm Development and Validation Study.

JMIR medical informatics·2026
Same author

A case report of high-titer FVIII inhibitor development after AAV-mediated gene therapy in hemophilia A.

Blood vessels, thrombosis & hemostasis·2026
Same author

Perioperative Outcomes in Factor XI Deficiency: A Systematic Review.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Related Experiment Video

Updated: Apr 5, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Individualizing factor replacement therapy in severe hemophilia.

Manuel D Carcao1, Alfonso Iorio2

  • 1Division of Haematology/Oncology and Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Seminars in Thrombosis and Hemostasis
|August 14, 2015
PubMed
Summary

Tailoring factor concentrate prophylaxis to individual severe hemophilia patients can improve outcomes. This approach considers patient-specific factors and resource availability for optimal treatment.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Related Experiment Videos

Last Updated: Apr 5, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Prophylactic factor concentrate replacement is standard for severe hemophilia.
  • Optimal prophylaxis regimens remain under investigation, with growing interest in personalized approaches.

Purpose of the Study:

  • To review concerns and strategies for tailoring prophylaxis regimens to individual severe hemophilia patients.
  • To discuss the application of these strategies to novel, longer-acting factor concentrates.

Main Methods:

  • Review of existing literature and clinical considerations for individualized hemophilia prophylaxis.
  • Analysis of factors influencing differential prophylaxis needs, including bleeding phenotype and pharmacokinetics.
  • Consideration of economic constraints in developing countries.

Main Results:

  • Individualized prophylaxis aims to match treatment to patient-specific needs, improving life expectancy and quality of life.
  • Variability in bleeding phenotype, factor pharmacokinetics, and activity levels necessitates tailored regimens.
  • Economic feasibility is a critical factor in implementing intensive prophylaxis.

Conclusions:

  • Tailoring prophylaxis offers a patient-centered approach to managing severe hemophilia.
  • Future strategies must incorporate new, longer-acting factor concentrates.
  • Personalized prophylaxis requires careful consideration of individual patient characteristics and global resource availability.